Qiagen N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
27 apr 2016 - 22:00
Statutaire naam
Qiagen N.V.
Titel
QIAGEN reports results for first quarter of 2016
Bericht
Adjusted net sales $298.4 million (+2% constant exchange rates, 0% actual); adjusted operating income $53.4 million; adjusted EPS $0.19 ($0.19 CER)
• Growth drivers leading QIAGEN’s Sample to Insight portfolio with double-digit CER growth and providing 35% of sales
o QuantiFERON latent TB test delivers over 25% CER growth
o QIAsymphony consumables growth at double-digit CER rate, platform on track to achieve more than 1,750 cumulative placements by end-2016
o Successful GeneReader NGS System launch amid strong customer feedback for the first truly complete Sample to Insight workflow
• Fourth $100 million share repurchase program announced
• Full-year 2016 CER targets for adjusted net sales and earnings growth reaffirmed
Datum laatste update: 03 januari 2026